Skip to main content
SpringerLink
Log in
Book cover

Diseases of the Gastroesophageal Mucosa pp 137–166Cite as

Gastroesophageal Reflux Disease

Diagnosis and Treatment

  • Chapter

  • 99 Accesses

Part of the book series: Clinical Gastroenterology ((CG))

Abstract

Gastroesophageal reflux disease (GERD) is a term used to describe the clinical manifestations of reflux of gastric contents into the esophagus. The manifestations range from heartburn to severe erosive esophagitis, Barrett’s esophagus, and adenocarcinoma of the esophagus. GERD has diverse clinical manifestations, and people differ significantly in their sensitivity to esophageal acid exposure. Some patients have classic symptoms and tissue injury, but many have esophageal symptoms without evidence of esophageal mucosal damage. A few have considerable mucosal damage and complications, such as Barrett’s esophagus without having symptoms.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klausner AG, Schindlbeck NE, Muller-Lissner SA. (1990) Symptoms in gastro-oesophageal reflux disease. Lancet 335: 205–208.

    Article  Google Scholar 

  2. Richter JE. (2000) Gastroesophageal reflux disease in the older patients: presentation, treatment, and complications. Am J Gastroenterol 95: 368–373.

    PubMed  CAS  Google Scholar 

  3. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. (1998) One-week omeprazole treatment in the diagnosis of gastro-esophageal reflux disease. Scand J Gastroenterol 33: 15–20.

    Article  PubMed  CAS  Google Scholar 

  4. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, etal. (1997) Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 92: 1997–2000.

    PubMed  CAS  Google Scholar 

  5. Schindlebeck NE, Klauser AG, Voderholzer WA, et al. (1995) Empiric therapy for gastroesophageal disease. Arch Intern Med 155: 1808–1812.

    Article  Google Scholar 

  6. Bate CM, Riley SA, Chapman RW, Durnin AT,Taylor MD. (1999) Evaluation of omeprazole as a cost-effective diagnostic test for gstro-oesophageal reflux disease. Aliment Pharmacol Ther 13: 59–66.

    CAS  Google Scholar 

  7. Harding SM, Guzzo MR, Richter JE. (1999) 24-hour esophageal pH testing in asthmatics: respiratory symptom correlation with esophageal acid events. Chest 115: 654–659.

    Google Scholar 

  8. Harding SM, Richter JE, Guzzo M, Schan C, Alexander R, Bradley L. (1996) Asthma and grastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 100: 395–405.

    Article  PubMed  CAS  Google Scholar 

  9. Schnatz PF, Castell DO, Castell JA. (1996) Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy. Am J Gastroenterol 91: 1715–1718.

    PubMed  CAS  Google Scholar 

  10. Hewson EG, Sinclair JW, Dalton CG, Richter JE. (1991) Twenty four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 90: 576–583.

    PubMed  CAS  Google Scholar 

  11. Katz PO. (1990) Ambulatory esophageal and hypopharyngeal pH monitoring in patients with hoarseness. Am J Gastroenterol 85: 38–40.

    PubMed  CAS  Google Scholar 

  12. Irwin RS, French CL, Curley FJ, Zawacki JK, Bennett FM. (1993) Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. Chest 104: 1511–1517.

    Article  PubMed  CAS  Google Scholar 

  13. Ott DJ, McManus CM, Ledbetter MS, Chen YM, Gelfand DW. (1997) Heartburn correlated to 24-hour pH monitoring and radiographic examination of the esophagus. Am J Gastroenterol 92: 1827–1830.

    PubMed  CAS  Google Scholar 

  14. Johnson BT, Troshinsky MB, Castell JA, Castell DO. (1996) Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol 91: 1181–1185.

    Google Scholar 

  15. Ott DJ, Kelley TF, Chen YM, Gelfand DW,Wu WC. (1991) Use of a marshmallow bolus for evaluating lower esophageal mucosal ring. Am J Gastroenterol 86: 817–820.

    CAS  Google Scholar 

  16. Ott DJ, Kelly TF, Chen YM, Gelfandt DW. (1991) Evaluation of the esophagus with a marshmallow bolus: clarifying the cause of dysphagia. Gastrointest Radiol 16:1–4.

    Article  PubMed  CAS  Google Scholar 

  17. Ormseth EJ, Wong RK. (1999) Reflux laryngitis: pathophysiology, diagnosis, and management. Am J Gastroenterol 94: 2812–2817.

    Article  PubMed  CAS  Google Scholar 

  18. DeVault KR. (1996) Current management of gastroesophageal reflux disease. Gastroenterologist 4: 24–32.

    PubMed  CAS  Google Scholar 

  19. Richter JE, Long JF. (1995) Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol 90: 423–430.

    PubMed  CAS  Google Scholar 

  20. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. (2000) Control of transient lower esophageal sphincter relaxations and reflux by the GABA agonist baclofen in normal subjects. Gastroenterology 118: 7–13.

    Article  PubMed  CAS  Google Scholar 

  21. Bell NJ, Burget D, Howden C, Wilkinson J, Hunt RH. (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51: 59–67.

    Article  PubMed  Google Scholar 

  22. Hatlebakk JG, Berstad A. (1996) Pharmacokinetic optimization in the treatment of gastro-esophageal reflux disease. Clin Pharmacokinet 31: 386–406.

    Article  PubMed  CAS  Google Scholar 

  23. Hunt RH. (1995) The relationship between the control of pH and healing and symptom relief in gastro-esophageal reflux disease. Aliment PharmacolTher 9: 307.

    Google Scholar 

  24. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. (1997) The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 19: 1013–1023.

    Article  PubMed  CAS  Google Scholar 

  25. Cloud ML, Offen WW, Robinson M. (1991) Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. Dig Dis Sci 86: 1735–1742.

    CAS  Google Scholar 

  26. Euler AR, Murdock RH Jr, Wilson TH, Silver MT, Parker SE, Powers L. (1993) Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 88: 520–524.

    PubMed  CAS  Google Scholar 

  27. Johnson NJ, Boyd EJS, Mills JG, Wood JR. (1989) Acute treatment of reflux esophagitis: a multicenter trial to compare 150 mg ranitidine bid with 300 mg ranitidine qid. Aliment Pharmacol Ther 3: 259–266.

    Article  PubMed  CAS  Google Scholar 

  28. Takeuchi K, Kajimura M, Kodaira M, Lin S, Hanai H, Kaneko E. (1999) Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonist. Dig Dis Sci 44: 1703–1709.

    Article  PubMed  CAS  Google Scholar 

  29. Huang JQ, Hunt RH. (1998) Meta-analysis of comparative trials for healing erosive esophagitis with proton pump inhibitors and H2-receptor antagonists. Gastroenterology 45: A155.

    Google Scholar 

  30. DeVault KR, Castell DO. (1995) Guidelines for the diagnosis and therapeutic approach to gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 155: 2165–2173.

    Article  PubMed  CAS  Google Scholar 

  31. Richter JE, Kovacs TO, Greski-Rose PA, Fisher R. (1999) Lansaprazole in the treatment of heartburn in patients without erosive esophagitis. Aliment Pharmacol Ther 13: 795–804.

    Article  PubMed  CAS  Google Scholar 

  32. Janisch HD, Huttemann W, Bouzo MH. (1998) Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepatogastroenterology 35: 125–127.

    Google Scholar 

  33. Geldof H, Hazelhoff B, Otten MH. (1993) Two different dose regiments of cisapride in the treatment of reflux esophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 7: 409–415.

    Article  PubMed  CAS  Google Scholar 

  34. Galmiche JP, Brandstatter G, Evreux M, Hentschel E, Kerstan E, Kratochvil P, Reichel W, Schutze K, Soule JC, Vitaux J. (1998) Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double-blind controlled trial. Gut 29: 675–681.

    Article  Google Scholar 

  35. Galmiche JP, Barthelemy P, Hamelin B. (1997) Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 11:765–773.

    Article  PubMed  CAS  Google Scholar 

  36. Richter JE, Sabesin SM, Kogut DG, Kerr RM, Wruble LD, Collen MJ. (1996) Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 91: 1766–1772.

    PubMed  CAS  Google Scholar 

  37. Robinson M, Decktor DL, Maton PN, Sabesin S, Roufail W, Kogut D, Roberts W, McCullough A, Pardoll P, Saco L. (1993) Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 7: 67–73.

    Article  PubMed  CAS  Google Scholar 

  38. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. (1997) Omeprazole 10 mg once daily, omeprazole 20 mg once daily, or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 32: 965–973.

    Article  PubMed  CAS  Google Scholar 

  39. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. (1996) Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 10: 529–539.

    Article  PubMed  CAS  Google Scholar 

  40. Zeitoun P, Rampal P, Barbier P, Isal JP, Eriksson S, Carlsson R. (1989) Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux. Results of a double-blind randomized multicenter trial in France and Belgium. Gastroenterol Clin Biol 3: 457–462.

    Google Scholar 

  41. Sandmark S, Carlsson R, Fausa O, Lundell L. (1988) Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 23: 625–632.

    Article  PubMed  CAS  Google Scholar 

  42. Havelund T, Laursen LS, Skoubo-Kristensen E, Andersen BN, Pedersen SA, Jensen KB, Fenger C, Hanberg-Sorensen F, Lauritsen K. (1988) Omeprazole and ranitidine in treatment of reflux oesophagitis: double-blind comparative trial. Br Med J 296: 89–92.

    Article  CAS  Google Scholar 

  43. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL. (1988) Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 33: 523–529.

    Article  PubMed  CAS  Google Scholar 

  44. Klinkenberg-Knol EC, Jansen JM, Festen HP, Meuwissen SG, Lamers CB. (1987) Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1: 349–351.

    Article  PubMed  CAS  Google Scholar 

  45. Dehn TC, Shepherd HA, Colins-Jones D, Kettlewell MG, Carroll NJ. (1990) Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 31: 509–513.

    Article  PubMed  CAS  Google Scholar 

  46. Bate CM, Keeling PW, O’Morain C, et al. (1990) Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluation. Gut 31: 968–972.

    Article  PubMed  CAS  Google Scholar 

  47. Lundell L. (1990) Prevention of relapse of reflux oesophagitis after endoscopie healing: the efficacy and safety of omeprazole compared with ranitidine. Digestion 47 (Suppl 1): 72–75.

    Article  PubMed  Google Scholar 

  48. Porro GB, Pace F, Peracchia A, Bonavina L, Vigneri S, Scialabba A, Franceschi M. (1992) Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 15: 192–198.

    Article  Google Scholar 

  49. James OF, Parry-Billings KS. (1994) Comparison of omeprazole and histamine H2-receptor antagonist in the treatment of elderly and young patients with reflux oesophagitis. Age Ageing 23: 121–126.

    Article  PubMed  CAS  Google Scholar 

  50. Maton PN, Orlando R, Joelsson B. (1999) Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial. Aliment Pharmacol Ther 13: 819–826.

    Article  PubMed  CAS  Google Scholar 

  51. Chiba N, Degara CJ, Wilkinson JM, Hunt RH. (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 112: 1798–1810.

    Article  PubMed  CAS  Google Scholar 

  52. Bardhan KD, Morris P, Thompson M, Dhande DS, Hinchliffe RF, Jones RB, Daly MJ, Carroll NJ. (1990) Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. Gut 31: 745–749.

    Article  PubMed  CAS  Google Scholar 

  53. Klinkenberg-Knol EC, Nelis F, Dent J, et al. (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118: 661–669.

    Article  PubMed  CAS  Google Scholar 

  54. Wilder-Smith CH, Van Niekerk N, Scholtz HE. (1999) How much is the action of different proton pump inhibitors affected by the time of dosing relative to food ingestion? Gastroenterology 116: G1544.

    Google Scholar 

  55. Kuo B, Castell DO. (1996) Optimal dosing of omeprazole 40 mg daily: Effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 91: 1532–1538.

    PubMed  CAS  Google Scholar 

  56. Peghini PL, Katz PO, Bracy NA, Castell DO. (1998) Nocturnal Recovery of Gastric acid Secretion With Twice-Daily Dosing of Proton Pump Inhibitor. Am J Gastroenterol 93: 763–766.

    Article  PubMed  CAS  Google Scholar 

  57. Peghini PL, Katz PO, Castell DO. (1998) Ranitidine controls nocturnal acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 115: 1335–1339.

    Article  PubMed  CAS  Google Scholar 

  58. Smout AJ, Geus WP, Mulder PG, Stockbrugger RW, Lamers CB. (1996) Gastro-oesophageal reflux disease in The Netherlands. Resultsof of a multicentre pH study. Scand J Gastroenterol 31 (Suppl 218): 10–15.

    Article  Google Scholar 

  59. Spechler SJ. (1992) Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 51: 24–29.

    Article  PubMed  Google Scholar 

  60. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. (2000) A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 95: 395–407.

    Article  PubMed  CAS  Google Scholar 

  61. Zagari M, Villa KF, Freston JW. (1995) Proton pump inhibitors versus H2-receptor antagonists for the treatment of erosive gastroesophageal reflux disease: A cost comparative study. Am J Man Care 3: 247–255.

    Google Scholar 

  62. DeVault KR, Castell DO. (1999) Updated guidelines for the diagnosis and treatment of gastrointestinal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 94: 1434–1442.

    Article  PubMed  CAS  Google Scholar 

  63. Hetzel DJ, Dent J, Reed WD, et al. (1988) Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903–912.

    PubMed  CAS  Google Scholar 

  64. Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M. (1996) Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 91: 1758–1765.

    PubMed  CAS  Google Scholar 

  65. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, Solcia E,Shearman DJ. (1994) Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 35: 590–598.

    CAS  Google Scholar 

  66. Hallerback B, Unge P, Carling L, Edwin B, Glise H, Havu N, Lyrenas E, Lundberg K. (1994) Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 107: 1305–1311.

    PubMed  CAS  Google Scholar 

  67. Vigneri S, Termini R, Leandro G, et al. (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106–1110.

    Article  PubMed  CAS  Google Scholar 

  68. Sontag SJ. (1993) Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther 7: 293–312.

    Article  PubMed  CAS  Google Scholar 

  69. Blum AL, Adami B, Bouzo MH, et al. (1993) Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 38: 551–560.

    Article  PubMed  CAS  Google Scholar 

  70. Tytgat GN, Anker Hansen OJ, Carling L, et al. (1992) Effect of cisapride on relapse of reflux oesophagitis, healed with antisecretory drug. Scand J Gastroenterol 27: 175–183.

    Article  PubMed  CAS  Google Scholar 

  71. Carr SJ, Wicks AC. (1992) Omeprazole and oesophageal stricture. Lancet 339: 316.

    Article  PubMed  CAS  Google Scholar 

  72. Marks RD, Richter JE, Rizzo J, Koehler RE, Spenney JG, Mills TP, Champion G. (1994) Omeprazole versus H2-receptor antagonist in treating patients with peptic stricture and esophagitis. Gastroenterology 106: 907–915.

    PubMed  CAS  Google Scholar 

  73. Freston JW. (1994) Omeprazole, hypergastrinemia and gastric carcinoids. Ann Intern Med 121: 232–233.

    PubMed  CAS  Google Scholar 

  74. Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Hakanson R, Olbe L, Solcia E, Walsh JH, Wolfe MM. (1995) Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells: A review and analysis. Dig Dis Sci 40 (Suppl): 50S - 62S.

    Article  PubMed  CAS  Google Scholar 

  75. Borch K., Renvall H, Liedberg G. (1985) Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 88: 634–648.

    Google Scholar 

  76. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. (1992) Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with Zollinger-Ellison syndrome. Gut 33: 1275–1279.

    Article  PubMed  CAS  Google Scholar 

  77. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. (1993) Longterm omeprazole therapy in peptic ulcer disease: gastrin endocrine cell growth, and gastritis. Gastroenterology 104: 1356–1370.

    PubMed  CAS  Google Scholar 

  78. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. (1992) Gastric endocrine cells in patients receiving long-term omeprazole treatment. Digestion 51 (Suppl 1): 82–92.

    Article  PubMed  Google Scholar 

  79. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. (1999) Safety profile of lansoprazole, A proton pump inhibitor: The U.S. clinical trial experience. Drug Safety 20: 195–205.

    Article  PubMed  CAS  Google Scholar 

  80. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, Fraumeni JF Jr. (1993) Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 71: 745–750.

    Article  PubMed  CAS  Google Scholar 

  81. Freston JW. (1997) Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective. Am J Gastroenterol 92:51 S-57S.

    Google Scholar 

  82. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. (1996) Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334: 1018–1022.

    Article  PubMed  CAS  Google Scholar 

  83. Lundell L, Miettinen P, Myrvold HE, et al. (1999) Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology 117: 319–326.

    Article  PubMed  CAS  Google Scholar 

  84. Stolte M, Bethke B, Ruhl G, Ritter M. (1992) Omeprazole-induced pseudo-hypertrophy of gastric parietal cells. Z Gastroenterol 30: 134–138.

    PubMed  CAS  Google Scholar 

  85. Driman DK, Wright C, Tougas G, Riddell RH. (1996) Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 41: 2039–2047.

    Article  PubMed  CAS  Google Scholar 

  86. Krishmamurthy S, Dayal Y. (1997) Parietal cell protrusions in gastric ulcer disease. Hum Pathol 28: 1126–1130.

    Article  Google Scholar 

  87. Graham JR. (1993) Omeprazole and gastric polyposis in humans. Gastroenterology 104: 1584.

    PubMed  CAS  Google Scholar 

  88. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen V, Sandvik AK. (1996) Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39: 649–653.

    Article  PubMed  CAS  Google Scholar 

  89. Gillen D, Wirz AA, Ardill JE, McColl KE. (1999) Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116: 239–247.

    Article  PubMed  CAS  Google Scholar 

  90. Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G, Russell RM. (1994) Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 106: 615–623.

    PubMed  CAS  Google Scholar 

  91. Elsborg L, Mosbech J. (1979) Pernicious anemia as a risk factor in gastric cancer. Acta Med Scand 206: 315–318.

    Article  PubMed  CAS  Google Scholar 

  92. Koop H. (1992) Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 6: 399–406.

    Article  PubMed  CAS  Google Scholar 

  93. Termanini B, Gibril F, Sutliff VE, Yu F, Vemzon DJ, Jensen RT. (1998) Effect of long-term gastric acid suppressive therapy on serum vitamin B 12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104: 422–430.

    Article  PubMed  CAS  Google Scholar 

  94. Koop H, Bachem MG. (1992) Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 14: 288–292.

    Article  PubMed  CAS  Google Scholar 

  95. Bellou A, Aimone-Gastin I, De Korwin JD, Bronowicki JP, Moneret VA, Nicolas JP, Bigard MA, Gueant JL. (1996) Cobalmin deficiency with megaloblastic anemia in one patient under long-term omeprazole therapy. J Intern Med 240: 161–164.

    Article  PubMed  CAS  Google Scholar 

  96. Kitang E, Schonsby H. (1987) Effect of gastric anacidity on the release of cobalamins from food and their subsequent binding to R-protein. Scand J Gastroenterol 22: 1031–1037.

    Article  Google Scholar 

  97. Nissen VR. (1956) Eine einfache operation zur beeinflussung der refluxoesophagitis. Scweizer Med Wochenschrift 86: 590–592.

    CAS  Google Scholar 

  98. DeMeester TR, Bonavina L, Albertucci M. (1986) Nissen fundoplication for gastroesophageal reflux disease: Evaluation of primary repair in 100 consecutive patients. Ann Surg 204: 9–20.

    Article  PubMed  CAS  Google Scholar 

  99. Kahrilas PJ. (1999) Laparoscopic antireflux surgery: silver bullet or the emperor’s new clothes. Am J Gastroenterol 94: 1721–1723.

    Article  PubMed  CAS  Google Scholar 

  100. Perdikis G, Hinder RA, Lund RJ, Raiser F. (1997) Laparoscopic Nissen fundoplication: Where do we stand? Surg Laparosc Endow 7: 17–21.

    Article  CAS  Google Scholar 

  101. DeMeester TR, Stein HJ. (1992) Minimizing the side effects of anti-reflux surgery. World J Surg 16: 335–336.

    Article  PubMed  CAS  Google Scholar 

  102. Ratannen TK, Halme TV, Luostarinen ME, Karhumaki LM, Kononen EO, Isolauri JO. (1999) The long-term results of open antireflux surgery in a community-based health care center. Am J Gastroenterol 94: 1777–1781.

    Article  Google Scholar 

  103. Soper NJ, Dunnegan D. (1999) Anatomic fundoplication failure after laparoscopie antireflux surgery. Ann Surg 229: 669–676.

    Article  PubMed  CAS  Google Scholar 

  104. Spechler SJ. (1992) Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 326: 786–792.

    Article  PubMed  CAS  Google Scholar 

  105. Lundell L, Miettinen P, Myrvold H, et al. (2000) Continued (5 years) follow-up of a randomised clinical study comparing anti-reflux surgery and omeprazole in gastroesophageal reflux disease. Gastroenterology 118(Suppl 2):Al217.

    Google Scholar 

Download references

Authors
  1. Jaroslaw H. Cymorek MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. Freston MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Connecticut Health Center, Farmington, CT, USA

    James W. Freston MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Cymorek, J.H., Freston, J.W. (2001). Gastroesophageal Reflux Disease. In: Freston, J.W. (eds) Diseases of the Gastroesophageal Mucosa. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-103-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-103-9_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9642-0

  • Online ISBN: 978-1-59259-103-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation